Shaperon Inc. 378800

KRX · South Korea · Health Technology

KRW 2,635.00+100.00 (+3.94%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Shaperon Inc. 378800

KRX · South Korea · Health Technology

KRW 2,635.00+100.00 (+3.94%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-67.96% · 6MFull-screen chart

Open KRW 2,565.00High KRW 2,750.00Low KRW 2,535.00Close KRW 2,635.00Volume 111.57K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 2,535.00
Day range: KRW 2,535.00 – KRW 2,750.00
52-week range: KRW 1,985.00 – KRW 13,650.00
Volume: 111.57K
Market cap: KRW 24.37B
Avg. volume (1Y): 245.45K

Performance

1 week

+3.33%

1 month

+6.90%

3 months

-1.86%

6 months

-67.75%

Year to date

-70.66%

1 year

-78.71%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: South Korea
Exchange: KRX
Shares outstanding: 9.25M
Employees: 53
ISIN: KR7378800007
Beta: -0.00

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceMar 03, 2026

Antibody-drug Conjugates (ADCs) in Oncology Market Competitive Landscape Report 2026: Comprehensive Insights About 200+ Companies and 220+ Drugs by Product Type, Stage, and Route of Administration

The market for Antibody-drug Conjugates (ADCs) in oncology presents significant opportunities with over 200 companies and 220 drugs in development globally. ADCs offer high specificity and reduced toxicity, targeting diverse cancer types. Collaborations and innovations, such as nanobody-based and engineered linker technologies, further expand potential.Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Antibody-drug Conjugates (ADCs) in Oncology - Competitive Landscape, 2026" report has been added

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.